BioVie (Nasdaq: BIVI) President and CEO Cuong Do joins us for an exclusive investor interview discussing BioVie’s late-clinical-stage pipeline and upcoming milestones across neurodegeneration and liver disease.In our conversation, Cuong outlines why BioVie is targeting TNFα-mediated inflammation and insulin resistance with bezisterim (formerly NE3107), plus the company’s second program, BIV201, for refractory ascites, a high-mortality complication of liver cirrhosis with no FDA-approved drug therapies today.BioVie is positioning for multiple catalysts across a differentiated clinical-stage portfolio targeting large unmet needs in neurodegeneration and liver disease, supported by an experienced leadership team.Watch the full interview for management’s full roadmap, trial design insights, and how the company is thinking about value creation over the next 12 months.👉 BioVie is a client of RedChip. To learn more about BIVI and to read our full disclosure, visit: https://www.BIVIinfo.com#BIVI #BioVie #BiotechStocks #SmallCapStocks #Investing #Parkinsons #LongCOVID #Alzheimers #ClinicalTrials #HealthcareInvesting

Lithium iron phosphate (LFP) batteries now power the majority of global battery production, but supply chains remain heavily concentrated in Asia. In our exclusive interview, First Phosphate (OTCQX: FRSPF | CSE: PHOS | FSE: KD0) CEO John Passalacqua explains how the company is working to onshore a full North American LFP supply chain, starting with high-purity igneous phosphate in Quebec and progressing downstream toward battery materials.Phosphate is a critical, heavy-by-mass input in LFP cathodes, so securing a North American supply becomes more important as demand grows across energy storage, data centers, and AI infrastructure. First Phosphate highlights its Quebec igneous phosphate as a potential advantage because higher-purity, low-contaminant feedstock can translate into more efficient production of battery-grade purified phosphoric acid versus many sedimentary sources.👉 First Phosphate is a client of RedChip. To learn more about FRSPF and to read our full disclosure, visit: https://www.FRSPFinfo.com#FRSPF #PHOS #BatteryMetals #LFP #EnergyStorage #CriticalMinerals #SmallCapStocks #MicroCapInvesting

In our investor-focused interview, Mark White, CEO of Nexalin Technology (Nasdaq: NXL), breaks down how the company is building a non-invasive neurostimulation platform aimed at major unmet needs across brain health, including depression, insomnia, PTSD/TBI, and Alzheimer’s/dementia.Nexalin’s mission is to lead what it calls the “brain health movement” with treatment designed to be safe, effective, and drug-free, supported by a growing body of peer-reviewed research and a roadmap centered on Mood, Military, and Memory.Nexalin’s edge is its frequency-based approach designed to emulate natural brain activity through Deep Intracranial Frequency Stimulation (DIFS™). Clinical validation includes peer-reviewed results published in Radiology showing improved cognition and stronger brain network connectivity in mild Alzheimer’s disease. Additional peer-reviewed findings point to broader potential, including blood pressure reduction in depression (Journal of Affective Disorders) and improved attention with normalized brain activity in ADHD (Molecular Psychiatry).👉 Nexalin Technology is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: https://www.NXLinfo.com#NXL #Nexalin #Nasdaq #SmallCapStocks #MicroCapStocks #StockMarket #GrowthStocks #BiotechStocks #MedTech #DigitalHealth #MedicalDevices #Neurostimulation